From Immunophysiology to Immunotherapy Ilya Pharma evolved from the internationally recognized research conducted by the laboratories of the co-founders Mia Phillipson, Professor of Physiology at Uppsala University, Sweden, and Stefan Roos, Professor at the Swedish […]
Two new studies jointly published in Nature: The Clinical Microbiome reveal that certain species of fungi in the gut play a key role in the development of immune dysregulation and some pediatric allergic diseases — and may […]
Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for […]
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial. […]
Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC. Additional participating investors include Gates Foundation, ATHOS […]
When the liver fails, toxins – such as ammonia – that should be filtered from the blood build up and reach the brain. The result is hepatic encephalopathy (HE), a devastating neurological complication of liver […]
EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome […]
mbiomics GmbH, a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases, today announced the successful third closing of its Series A round at €12 million, bringing the total round size to […]
Freya Biosciences, a clinical-stage immunology company developing therapies to treat inflammation and immune dysregulation in women, today announces positive topline results from its Phase 1 first-in-human clinical study evaluating FB301, a defined multi-strain Lactobacillus consortium […]
A global team of experts has identified a promising new approach to prevent recurrence of bacterial vaginosis (BV), a condition that affects millions of women worldwide. In a phase 1 randomized clinical trial of women […]
The new QIAsprint Connect is a next generation system for automated high-throughput nucleic acid purification, bringing together walk-away automation, flexible workflows and sustainable design – built for labs that want more control and less manual handling: High-throughput […]